Bisphosphonates pathway
- 1 January 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 21 (1), 50-53
- https://doi.org/10.1097/fpc.0b013e328335729c
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosisCurrent Medical Research and Opinion, 2008
- Bisphosphonate therapy for osteogenesis imperfectaPublished by Wiley ,2007
- Alendronate and Atrial FibrillationThe New England Journal of Medicine, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences of the United States of America, 2006
- Pharmacokinetics/Pharmacodynamics of BisphosphonatesClinical Pharmacokinetics, 2005
- Bisphosphonates and CancerJournal of Veterinary Internal Medicine, 2004
- Pharmacokinetics of AlendronateClinical Pharmacokinetics, 1999
- Cyclic Administration of Pamidronate in Children with Severe Osteogenesis ImperfectaThe New England Journal of Medicine, 1998